Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2311 to 2325 of 9061 results

  1. Deucravacitinib for treating systemic lupus erythematosus [TSID12405]

    Awaiting development Reference number: GID-TA12035 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Mezigdomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatment lines [TSID12402]

    Awaiting development Reference number: GID-TA12030 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Helge for detecting haemolysis

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  4. Vonicog alfa for preventing haemorrhage in people with von Willebrand disease when desmopressin is ineffective or not suitable [ID6272]

    Topic prioritisation

    Topic prioritisation

  5. Spectra Optia for plasma exchange, (MT828)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  6. Zanubrutinib for Chronic lymphocytic leukaemia (CLL) or Follicular lymphoma or Marginal zone lymphoma (MZL) or Waldenstrom's macroglobulinaemia [ID12199]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Mosunetuzumab for treating relapsed or refractory follicular lymphoma [TSID 12081]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Epcoritamab + R-CHOP for Diffuse large B-cell lymphoma (DLBCL) [TSID12334]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Gilteritinib + daunorubicin + cytarabine for Acute myeloid leukaemia (AML) [TSID12331]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]

    In development Reference number: GID-TA11334 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Percutaneous insertion of a cerebral protection device during TAVI for preventing stroke

    In development Reference number: GID-HTG10881 Expected publication date:  11 February 2027

    HealthTech guidance
    In development

  12. Secukinumab for treating relapsed polymyalgia rheumatica ID6599

    In development Reference number: GID-TA11806 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Spartan RX point-of-care CYP2C19 test

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  14. trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MT604) (MIB268)

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  15. CADScor system for ruling out coronary artery disease in people with symptoms of stable coronary artery disease (MT434

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation